Form 4: Vigil Neuroscience CFO Receives Stock Option Grant

Jennifer Lynn Ziolkowski, CFO of Vigil Neuroscience, Inc., was granted stock options to purchase 156,000 shares of common stock on March 1, 2024.

Summary

• Jennifer Lynn Ziolkowski, the Chief Financial Officer of Vigil Neuroscience, Inc., received a stock option grant on March 1, 2024.
• The grant allows her to purchase 156,000 shares of Vigil Neuroscience's common stock at an exercise price of $3.39 per share.
• The options vest in 48 equal monthly installments, beginning on April 1, 2024, and expire on March 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard business practice (stock option grant) and doesn't contain any alarming or negative information. It's a neutral event with a slightly positive implication for aligning management incentives.

Positives

• The stock option grant aligns the CFO's interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements beyond the details of the stock option grant.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant and vesting schedule are typical for a CFO role in a company of Vigil Neuroscience's size and stage of development.
• Comparable companies like Amylyx Pharmaceuticals or Biogen also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CFO's interests with the company's long-term success.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates